In this article
On April 11, 2025, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
The effectiveness was evaluated in CHECKMATE-9DW (NCT04039607), a study where 668 people with inoperable or advanced liver cancer (HCC) were randomly assigned to two groups. Patients had a confirmed diagnosis of hepatocellular carcinoma (HCC), were in Child-Pugh Class A, had an Eastern Cooperative Oncology Group (ECOG) performance level of 0 or 1, and had not received any previous systemic treatment for their advanced disease.
Patients were randomly assigned to get either nivolumab 1 mg/kg through an IV along with ipilimumab 3 mg/kg IV every 3 weeks for up to 4 doses, then continue with nivolumab 480 mg IV every 4 weeks, or the doctor's choice of lenvatinib or sorafenib.
The principal effectiveness outcome measure was overall survival (OS) among all randomized participants. The overall response rate (ORR), which was assessed by a separate review team using RECIST 1.1 guidelines, was another measure of how effective the treatment was. The average time patients lived (OS) was 23.7 months for the nivolumab + ipilimumab group and 20.6 months for the lenvatinib or sorafenib group, with a hazard ratio of 0.79 and a p-value of less than 0.0180. The overall response rate (ORR) was 36.1% (95% CI: 31.0, 41.5) in one arm and 13.2% (95% CI: 9.8, 17.3) in the other arm (p-value <0.0001).
The predominant adverse effects (>20%) included rash, pruritus, tiredness, and diarrhea.
The recommended dose of nivolumab is 1 mg for every kilogram of body weight, given together with ipilimumab at 3 mg per kilogram through an IV every three weeks for up to four doses. Following this, administer nivolumab at a dose of 240 mg via an IV every two weeks, or 480 mg through an IV alone every four weeks.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Related Articles
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.